Literature DB >> 12362293

Natural history of recurrent hepatitis C.

Marina Berenguer1.   

Abstract

1. After liver transplantation for hepatitis C virus (HCV)-related cirrhosis, recurrence of infection is universal, with development of histological hepatitis in the majority of patients. 2. The natural history of recurrent hepatitis C is highly variable. Although 30% to 50% of patients develop posttransplantation viremia with minimal liver injury, 10% to 30% progress to cirrhosis after a median of 5 years. 3. Progression of hepatitis C is accelerated in immunocompromised liver transplant recipients compared with immunocompetent patients, both before and after the development of compensated cirrhosis. 4. HCV-related disease progression is faster in patients who underwent transplantation in recent years compared with those who underwent transplantation earlier. 5. HCV infection significantly impairs patient and allo-graft survival after liver transplantation. 6. Several variables, including donor age, degree of immunosuppression, viral load either pretransplantation or early posttransplantation, timing of recurrence, and early histological findings, are implicated in the outcome of hepatitis C posttransplantation.

Entities:  

Mesh:

Year:  2002        PMID: 12362293     DOI: 10.1053/jlts.2002.35781

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  45 in total

1.  Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.

Authors:  Dario Cattaneo; Salvatore Sollima; Nitin Charbe; Chiara Resnati; Emilio Clementi; Cristina Gervasoni
Journal:  Eur J Clin Pharmacol       Date:  2015-09-12       Impact factor: 2.953

2.  Impact of donor and recipient race on survival after hepatitis C-related liver transplantation.

Authors:  Jennifer E Layden; Scott J Cotler; Shellee A Grim; Michael J Fischer; Michael R Lucey; Nina M Clark
Journal:  Transplantation       Date:  2012-02-27       Impact factor: 4.939

3.  Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis.

Authors:  Ashley M Lakner; Nury M Steuerwald; Tracy L Walling; Sriparna Ghosh; Ting Li; Iain H McKillop; Mark W Russo; Herbert L Bonkovsky; Laura W Schrum
Journal:  Hepatology       Date:  2012-06-18       Impact factor: 17.425

Review 4.  Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop.

Authors:  Kymberly D S Watt; Kelly Burak; Marc Deschênes; Les Lilly; Denis Marleau; Paul Marotta; Andrew Mason; Kevork M Peltekian; Eberhard L Renner; Eric M Yoshida
Journal:  Can J Gastroenterol       Date:  2006-11       Impact factor: 3.522

5.  Successful treatment of fulminant hepatitis C by therapy with alpha interferon and ribavirin.

Authors:  Ming-Lung Yu; Nai-Jen Hou; Chia-Yen Dai; Wen-Yu Chang; Wan-Long Chuang
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 6.  De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature.

Authors:  Anca Croitoru; Thomas D Schiano; Myron Schwartz; Sasan Roayaie; Ruliang Xu; Arief Suriawinata; M Isabel Fiel
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

Review 7.  The management of patients awaiting liver transplantation.

Authors:  Ka-Kit Li; James Neuberger
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-10-06       Impact factor: 46.802

8.  Survival in liver transplant recipients with hepatitis B- or hepatitis C-associated hepatocellular carcinoma: the Chinese experience from 1999 to 2010.

Authors:  Zhenhua Hu; Jie Zhou; Haibo Wang; Min Zhang; Shaogang Li; Yuzhou Huang; Jian Wu; Zhiwei Li; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

9.  Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis.

Authors:  A J Demetris; B Eghtesad; A Marcos; K Ruppert; M A Nalesnik; P Randhawa; T Wu; A Krasinskas; P Fontes; T Cacciarelli; A O Shakil; N Murase; J J Fung; T E Starzl
Journal:  Am J Surg Pathol       Date:  2004-05       Impact factor: 6.394

10.  Persistence of hepatitis C RNA in liver allografts is associated with histologic progression independent of serologic viral clearance.

Authors:  M Ghabril; R C Dickson; M Krishna; R Lloyd; J Aranda-Michel; A Keaveny; R Satyanarayana; H Bonatti
Journal:  J Transplant       Date:  2009-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.